Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $396.4 million.

  • Praxis Precision Medicines' Liabilities and Shareholders Equity fell 4.77% to $396.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 51.47%. This contributed to the annual value of $483.1 million for FY2024, which is 449.31% up from last year.
  • According to the latest figures from Q3 2025, Praxis Precision Medicines' Liabilities and Shareholders Equity is $396.4 million, which was down 12.46% from $452.8 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Liabilities and Shareholders Equity ranged from a high of $483.1 million in Q4 2024 and a low of $87.9 million during Q4 2023.
  • In the last 3 years, Praxis Precision Medicines' Liabilities and Shareholders Equity had a median value of $396.4 million in 2025 and averaged $304.1 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Liabilities and Shareholders Equity tumbled by 58.92% in 2023, and later soared by 449.31% in 2024.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Liabilities and Shareholders Equity stood at $115.1 million in 2022, then declined by 23.61% to $87.9 million in 2023, then soared by 449.31% to $483.1 million in 2024, then declined by 4.77% to $396.4 million in 2025.
  • Its last three reported values are $396.4 million in Q3 2025, $452.8 million for Q2 2025, and $478.7 million during Q1 2025.